Name | Number of supported studies | Average coverage | |
---|---|---|---|
GABAergic neuron | 3 studies | 20% ± 3% | |
glutamatergic neuron | 3 studies | 27% ± 6% |
Insufficient scRNA-seq data for expression of CIP2A at tissue level.
Tissue | GTEx Coverage | GTEx Average TPM | GTEx Number of samples | TCGA Coverage | TCGA Average TPM | TCGA Number of samples |
---|---|---|---|---|---|---|
esophagus | 99% | 238.10 | 1436 / 1445 | 99% | 15.25 | 181 / 183 |
uterus | 100% | 240.73 | 170 / 170 | 98% | 17.09 | 451 / 459 |
ovary | 99% | 295.20 | 179 / 180 | 97% | 8.82 | 417 / 430 |
intestine | 100% | 216.88 | 964 / 966 | 96% | 10.06 | 507 / 527 |
breast | 100% | 178.32 | 459 / 459 | 95% | 9.88 | 1057 / 1118 |
bladder | 100% | 176.52 | 21 / 21 | 94% | 10.97 | 473 / 504 |
lung | 97% | 166.39 | 563 / 578 | 94% | 11.90 | 1080 / 1155 |
skin | 98% | 674.15 | 1768 / 1809 | 88% | 9.91 | 416 / 472 |
stomach | 89% | 127.84 | 320 / 359 | 96% | 10.16 | 274 / 286 |
brain | 93% | 186.01 | 2453 / 2642 | 84% | 4.84 | 595 / 705 |
prostate | 99% | 187.91 | 243 / 245 | 66% | 2.44 | 330 / 502 |
kidney | 94% | 124.53 | 84 / 89 | 69% | 3.45 | 625 / 901 |
pancreas | 62% | 47.66 | 203 / 328 | 91% | 5.26 | 162 / 178 |
adrenal gland | 100% | 184.86 | 257 / 258 | 52% | 2.16 | 120 / 230 |
thymus | 100% | 174.33 | 650 / 653 | 51% | 2.32 | 306 / 605 |
lymph node | 0% | 0 | 0 / 0 | 100% | 16.97 | 29 / 29 |
spleen | 100% | 408.14 | 241 / 241 | 0% | 0 | 0 / 0 |
tonsil | 0% | 0 | 0 / 0 | 100% | 23.46 | 45 / 45 |
adipose | 100% | 177.91 | 1200 / 1204 | 0% | 0 | 0 / 0 |
blood vessel | 100% | 168.58 | 1329 / 1335 | 0% | 0 | 0 / 0 |
heart | 86% | 105.10 | 740 / 861 | 0% | 0 | 0 / 0 |
muscle | 82% | 75.16 | 659 / 803 | 0% | 0 | 0 / 0 |
liver | 38% | 44.63 | 85 / 226 | 43% | 2.28 | 173 / 406 |
peripheral blood | 64% | 653.34 | 593 / 929 | 0% | 0 | 0 / 0 |
eye | 0% | 0 | 0 / 0 | 10% | 0.27 | 8 / 80 |
abdomen | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
bone marrow | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
diaphragm | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
gingiva | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasal cavity | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nasopharynx | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
nose | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
placenta | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
spinal column | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 0 |
ureter | 0% | 0 | 0 / 0 | 0% | 0 | 0 / 1 |
GO_0006974 | Biological process | DNA damage response |
GO_0141112 | Biological process | broken chromosome clustering |
GO_0051276 | Biological process | chromosome organization |
GO_0005694 | Cellular component | chromosome |
GO_0005829 | Cellular component | cytosol |
GO_0005886 | Cellular component | plasma membrane |
GO_0005737 | Cellular component | cytoplasm |
GO_0004864 | Molecular function | protein phosphatase inhibitor activity |
GO_0045296 | Molecular function | cadherin binding |
GO_0042803 | Molecular function | protein homodimerization activity |
GO_0005515 | Molecular function | protein binding |
Gene name | CIP2A |
Protein name | NOCIVA Cellular inhibitor of PP2A Protein CIP2A (Cancerous inhibitor of PP2A) (p90 autoantigen) |
Synonyms | KIAA1524 |
Description | FUNCTION: Acts as an inhibitor of protein phosphatase PP2A . Promotes anchorage-independent cell growth and tumor formation by preventing dephosphorylation of MYC, thereby stabilizing MYC in human malignancies . Together with TOPBP1, plays an essential role in the response to genome instability generated by the presence of acentric chromosome fragments derived from shattered chromosomes within micronuclei . Micronuclei, which are frequently found in cancer cells, consist of chromatin surrounded by their own nuclear membrane: following breakdown of the micronuclear envelope, a process associated with chromothripsis, the CIP2A-TOPBP1 complex tethers chromosome fragments during mitosis to ensure clustered segregation of the fragments to a single daughter cell nucleus, facilitating re-ligation with limited chromosome scattering and loss . . |
Accessions | F8WF26 ENST00000491772.5 [Q8TCG1-2] ENST00000468953.1 ENST00000481530.5 A0A894J8Q9 ENST00000625495.1 ENST00000295746.13 [Q8TCG1-1] F8WAX6 Q8TCG1 |